Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-12-2017 | Original Paper

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance

Authors: Chiara Fabbri, Concetta Crisafulli, Raffaella Calati, Diego Albani, Gianluigi Forloni, Marco Calabrò, Rosalba Martines, Siegfried Kasper, Joseph Zohar, Alzbeta Juven-Wetzler, Daniel Souery, Stuart Montgomery, Julien Mendlewicz, Alessandro Serretti

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 8/2017

Abstract

Genes belonging to neuroplasticity, monoamine, circadian rhythm, and transcription factor pathways were investigated as modulators of antidepressant efficacy. The present study aimed (1) to replicate previous findings in an independent sample with treatment-resistant depression (TRD), and (2) to perform a pathway analysis to investigate the possible molecular mechanisms involved. 220 patients with major depressive disorder who were non-responders to a previous antidepressant were treated with venlafaxine for 4–6 weeks and in case of non-response with escitalopram for 4–6 weeks. Symptoms were assessed using the Montgomery Asberg Depression Rating Scale. The phenotypes were response and remission to venlafaxine, non-response (TRDA) and non-remission (TRDB) to neither venlafaxine nor escitalopram. 50 tag SNPs in 14 genes belonging to the pathways of interest were tested for association with phenotypes. Molecular pathways (KEGG database) that included one or more of the genes associated with the phenotypes were investigated also in the STAR*D sample. The associations between ZNF804A rs7603001 and response, CREB1 rs2254137 and remission were replicated, as well as CHL1 rs2133402 and lower risk of TRD. Other CHL1 SNPs were potential predictors of TRD (rs1516340, rs2272522, rs1516338, rs2133402). The MAPK1 rs6928 SNP was consistently associated with all the phenotypes. The protein processing in endoplasmic reticulum pathway (hsa04141) was the best pathway that may explain the mechanisms of MAPK1 involvement in antidepressant response. Signals in genes previously associated with antidepressant efficacy were confirmed for CREB1, ZNF804A and CHL1. These genes play pivotal roles in synaptic plasticity, neural activity and connectivity.

Available only for authorised users

Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40. doi:10.1176/appi.ajp.163.1.28 CrossRefPubMed

Souery D, Calati R, Papageorgiou K et al. (2014) What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. World J Biol Psychiatry: 1–11. doi:10.3109/15622975.2014.987814

Ruhe HG, Huyser J, Swinkels JA et al (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836–1855CrossRefPubMed

Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242. doi:10.1056/NEJMoa052963 CrossRefPubMed

Bschor T, Baethge C (2010) No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 121:174–179. doi:10.1111/j.1600-0447.2009.01458.x CrossRefPubMed

Souery D, Serretti A, Calati R et al (2011) Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 31:512–516. doi:10.1097/JCP.0b013e3182228619 CrossRefPubMed

Schosser A, Serretti A, Souery D et al (2012) European Group for the Study of Resistant Depression (GSRD)–where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 22:453–468. doi:10.1016/j.euroneuro.2012.02.006 CrossRefPubMed

Fabbri C, Marsano A, Albani D et al (2014) PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J 14:463–472. doi:10.1038/tpj.2014.15 CrossRefPubMed

Fabbri C, Crisafulli C, Gurwitz D et al (2015) Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics J 15:538–548. doi:10.1038/tpj.2015.15 CrossRefPubMed

10.

Calati R, Crisafulli C, Balestri M et al (2013) Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 44:271–278. doi:10.1016/j.pnpbp.2013.03.005 CrossRefPubMed

11.

Zobel A, Maier W (2010) Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 260:407–417. doi:10.1007/s00406-009-0091-4 CrossRefPubMed

12.

Fabbri C, Serretti A (2015) Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep 17:50. doi:10.1007/s11920-015-0594-9 CrossRefPubMed

13.

Fabbri C, Di Girolamo G, Serretti A (2013) Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 162B:487–520. doi:10.1002/ajmg.b.32184 CrossRefPubMed

14.

Niitsu T, Fabbri C, Bentini F et al (2013) Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 45:183–194. doi:10.1016/j.pnpbp.2013.05.011 CrossRefPubMed

15.

Maness PF, Schachner M (2007) Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci 10:19–26. doi:10.1038/nn1827 CrossRefPubMed

16.

Morellini F, Lepsveridze E, Kahler B et al (2007) Reduced reactivity to novelty, impaired social behavior, and enhanced basal synaptic excitatory activity in perforant path projections to the dentate gyrus in young adult mice deficient in the neural cell adhesion molecule CHL1. Mol Cell Neurosci 34:121–136. doi:10.1016/j.mcn.2006.10.006 CrossRefPubMed

17.

Desarnaud F, Jakovcevski M, Morellini F et al (2008) Stress downregulates hippocampal expression of the adhesion molecules NCAM and CHL1 in mice by mechanisms independent of DNA methylation of their promoters. Cell Adhes Migr 2:38–44CrossRef

18.

Morag A, Pasmanik-Chor M, Oron-Karni V et al (2011) Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12:171–184. doi:10.2217/pgs.10.185 CrossRefPubMed

19.

Xia Z, Storm DR (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 6:267–276. doi:10.1038/nrn1647 CrossRefPubMed

20.

McAuley EZ, Scimone A, Tiwari Y et al (2012) Identification of sialyltransferase 8B as a generalized susceptibility gene for psychotic and mood disorders on chromosome 15q25-26. PLoS One 7:e38172. doi:10.1371/journal.pone.0038172 CrossRefPubMedPubMedCentral

21.

Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347. doi:10.1146/annurev.pharmtox.011008.145634 CrossRefPubMed

22.

Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391–426CrossRefPubMed

23.

Maes M, Fisar Z, Medina M et al (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20:127–150. doi:10.1007/s10787-011-0111-7 CrossRefPubMed

24.

Tsai SJ, Liou YJ, Hong CJ et al (2008) Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 8:384–390. doi:10.1038/sj.tpj.6500486 CrossRefPubMed

25.

Murakami M, Kambe T, Shimbara S et al (1999) Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 274:3103–3115CrossRefPubMed

26.

O’Banion MK (1999) Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 13:45–82CrossRefPubMed

27.

Garcia MC, Kim HY (1997) Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res 768:43–48CrossRefPubMed

28.

Basselin M, Chang L, Bell JM et al (2006) Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31:1659–1674. doi:10.1038/sj.npp.1300920 CrossRefPubMed

29.

Rao JS, Ertley RN, Lee HJ et al (2006) Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J 6:413–420. doi:10.1038/sj.tpj.6500391 CrossRefPubMed

30.

Pae CU, Yu HS, Kim JJ et al (2004) BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. NeuropsychoBiology 49:185–188. doi:10.1159/000077364 CrossRefPubMed

31.

Chen Z, Gibson TB, Robinson F et al (2001) MAP kinases. Chem Rev 101:2449–2476CrossRefPubMed

32.

Schafe GE, Atkins CM, Swank MW et al (2000) Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci 20:8177–8187PubMed

33.

Sweatt JD (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76:1–10CrossRefPubMed

34.

Bogoyevitch MA, Court NW (2004) Counting on mitogen-activated protein kinases–ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16:1345–1354. doi:10.1016/j.cellsig.2004.05.004 CrossRefPubMed

35.

Qi H, Mailliet F, Spedding M et al (2009) Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology 56:37–46. doi:10.1016/j.neuropharm.2008.06.068 CrossRefPubMed

36.

Gourley SL, Wu FJ, Taylor JR (2008) Corticosterone regulates pERK1/2 map kinase in a chronic depression model. Ann N Y Acad Sci 1148:509–514. doi:10.1196/annals.1410.076 CrossRefPubMedPubMedCentral

37.

Qi X, Lin W, Li J et al (2008) Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 31:278–285. doi:10.1016/j.nbd.2008.05.003 CrossRefPubMed

38.

Hisaoka K, Nishida A, Koda T et al (2001) Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 79:25–34CrossRefPubMed

39.

Lin TY, Yang TT, Lu CW et al (2011) Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals. Prog Neuropsychopharmacol Biol Psychiatry 35:598–606. doi:10.1016/j.pnpbp.2010.12.029 CrossRefPubMed

40.

Labasque M, Meffre J, Carrat G et al (2010) Constitutive activity of serotonin 2 C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants. Mol Pharmacol 78:818–826. doi:10.1124/mol.110.066035 CrossRefPubMed

41.

Malki K, Lourdusamy A, Binder E et al (2012) Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression. Pharmacogenet Genom 22:765–776. doi:10.1097/FPC.0b013e328356fa90 CrossRef

42.

Hardingham GE, Arnold FJ, Bading H (2001) A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication. Nat Neurosci 4:565–566. doi:10.1038/88380 CrossRefPubMed

43.

Davis S, Vanhoutte P, Pages C et al (2000) The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci 20:4563–4572PubMed

44.

Ying SW, Futter M, Rosenblum K et al (2002) Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci 22:1532–1540PubMed

45.

Murphy GM Jr, Sarginson JE, Ryan HS et al (2013) BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet Genom 23:301–313. doi:10.1097/FPC.0b013e328360b175 CrossRef

46.

Serretti A, Chiesa A, Calati R et al (2011) A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 128:56–63. doi:10.1016/j.jad.2010.06.025 CrossRefPubMed

47.

Esslinger C, Kirsch P, Haddad L et al (2011) Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 54:2514–2523. doi:10.1016/j.neuroimage.2010.10.012 CrossRefPubMed

48.

Lencz T, Szeszko PR, DeRosse P et al (2010) A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 35:2284–2291. doi:10.1038/npp.2010.102 CrossRefPubMedPubMedCentral

49.

Lett TA, Zai CC, Tiwari AK et al (2011) ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. World J Biol Psychiatry 12:392–397. doi:10.3109/15622975.2011.564655 CrossRefPubMed

50.

Williams HJ, Craddock N, Russo G et al (2011) Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Genet 20:387–391. doi:10.1093/hmg/ddq471 CrossRefPubMed

51.

Shi J, Potash JB, Knowles JA et al (2011) Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 16:193–201. doi:10.1038/mp.2009.124 CrossRefPubMed

52.

Shyn SI, Shi J, Kraft JB et al (2011) Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol Psychiatry 16:202–215. doi:10.1038/mp.2009.125 CrossRefPubMed

53.

Zhou X, Qyang Y, Kelsoe JR et al (2007) Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Behav 6:269–276. doi:10.1111/j.1601-183X.2006.00256.x CrossRefPubMed

54.

Mao X, Yang SH, Simpkins JW et al (2007) Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons. J Neurochem 100:1300–1314. doi:10.1111/j.1471-4159.2006.04297.x CrossRefPubMedPubMedCentral

55.

Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15(2):R271–R277. doi:10.1093/hmg/ddl207.CrossRefPubMed

56.

Terracciano A, Tanaka T, Sutin AR et al (2010) Genome-wide association scan of trait depression. Biol Psychiatry 68:811–817. doi:10.1016/j.biopsych.2010.06.030 CrossRefPubMedPubMedCentral

57.

Garriock HA, Kraft JB, Shyn SI et al (2010) A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67:133–138. doi:10.1016/j.biopsych.2009.08.029 CrossRefPubMedPubMedCentral

58.

Hughes AT, Guilding C, Piggins HD (2011) Neuropeptide signaling differentially affects phase maintenance and rhythm generation in SCN and extra-SCN circadian oscillators. PLoS One 6:e18926. doi:10.1371/journal.pone.0018926 CrossRefPubMedPubMedCentral

59.

Soria V, Martinez-Amoros E, Escaramis G et al (2010) Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 35:1279–1289. doi:10.1038/npp.2009.230 CrossRefPubMedPubMedCentral

60.

Howland RH (2008) Sequenced treatment alternatives to relieve depression (STAR*D). Part 1: study design. J Psychosoc Nurs Ment Health Serv 46:21–24CrossRef

61.

Trivedi MH, Rush AJ, Ibrahim HM et al (2004) The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34:73–82CrossRefPubMed

62.

Gaynes BN, Warden D, Trivedi MH et al (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60:1439–1445. doi:10.1176/appi.ps.60.11.1439 CrossRefPubMed

63.

Pintor L, Torres X, Navarro V et al (2004) Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up? J Affect Disord 82:291–296. doi:10.1016/j.jad.2003.11.008 CrossRefPubMed

64.

Faul F, Erdfelder E, Lang AG et al (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191CrossRefPubMed

65.

Egan MF, Kojima M, Callicott JH et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269CrossRefPubMed

66.

Bath KG, Jing DQ, Dincheva I et al (2012) BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 37:1297–1304. doi:10.1038/npp.2011.318 CrossRefPubMedPubMedCentral

67.

Lisachev PD, Pustyl’nyak VO, Shtark MB (2014) Expression of Bcl2 family genes in the early phase of long-term potentiation. Bull Exp Biol Med 158:77–79. doi:10.1007/s10517-014-2696-5 CrossRefPubMed

68.

Liu ME, Huang CC, Yang AC et al (2013) Effect of Bcl-2 rs956572 polymorphism on age-related gray matter volume changes. PLoS One 8:e56663. doi:10.1371/journal.pone.0056663 CrossRefPubMedPubMedCentral

69.

Tamasi V, Petschner P, Adori C et al (2014) Transcriptional evidence for the role of chronic venlafaxine treatment in neurotrophic signaling and neuroplasticity including also Glutamatergic [corrected]—and insulin-mediated neuronal processes. PLoS One 9:e113662. doi:10.1371/journal.pone.0113662 CrossRefPubMedPubMedCentral

70.

Shishkina GT, Kalinina TS, Berezova IV et al (2012) Stress-induced activation of the brainstem Bcl-xL gene expression in rats treated with fluoxetine: correlations with serotonin metabolism and depressive-like behavior. Neuropharmacology 62:177–183. doi:10.1016/j.neuropharm.2011.06.016 CrossRefPubMed

71.

Kosten TA, Galloway MP, Duman RS et al (2008) Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 33:1545–1558. doi:10.1038/sj.npp.1301527 CrossRefPubMed

72.

Boulle F, Massart R, Stragier E et al (2014) Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Transl. Psychiatry 4:e485. doi:10.1038/tp.2014.125

73.

Perera TD, Coplan JD, Lisanby SH et al (2007) Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 27:4894–4901. doi:10.1523/JNEUROSCI.0237-07.2007 CrossRefPubMed

74.

Zhang C, Wu Z, Hong W et al (2014) Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. J Affect Disord 155:288–294. doi:10.1016/j.jad.2013.11.010 CrossRefPubMed

75.

Lohmann E, Periquet M, Bonifati V et al (2003) How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 54:176–185. doi:10.1002/ana.10613 CrossRefPubMed

76.

Khan NL, Graham E, Critchley P et al (2003) Parkin disease: a phenotypic study of a large case series. Brain 126:1279–1292CrossRefPubMed

77.

Yamamura Y, Hattori N, Matsumine H et al (2000) Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Development 22(Suppl 1):S87–S91CrossRefPubMed

78.

Kasten M, Kertelge L, Tadic V et al (2012) Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson’s disease. Mov Disord 27:754–759. doi:10.1002/mds.24999 CrossRefPubMed

Title: Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance
Authors: Chiara Fabbri
Concetta Crisafulli
Raffaella Calati
Diego Albani
Gianluigi Forloni
Marco Calabrò
Rosalba Martines
Siegfried Kasper
Joseph Zohar
Alzbeta Juven-Wetzler
Daniel Souery
Stuart Montgomery
Julien Mendlewicz
Alessandro Serretti
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 8/2017
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-017-0766-1

At a glance: The STEP trials

Springer Medicine

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study

Seizure threshold increases can be predicted by EEG quality in right unilateral ultrabrief ECT

Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines

On the search of new treatment strategies in patients with affective disorders

Is prepulse modification altered by continuous theta burst stimulation? DAT1 genotype and motor threshold interact on prepulse modification following brain stimulation

Polymorphism of the brain-derived neurotrophic factor and dynamics of the seizure threshold of electroconvulsive therapy